Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

Countries covered: United States Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on specific clinical decisions. Patient progression reveals: Decisions in treatment throughout patient stages Factors influencing their decisions Barriers to optimal care Confidence in treatment. Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Triple Positive Metastatic Breast Cancer. Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. This report allows you to: Understand what occurs with actual patients Access the most up-to-date prescribing trends Gain actionable data for developing and improving your market strategies Pinpoint needs of your target audience Focus resources to maximize the effectiveness of your budget Understand where your product fits Understand where your competitor’s product fits Design messages to advance brand performance Patient specific case scenario that unfold throughout the report, presented to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on clinical decisions. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.

Additional Information

Report Excerpt

Introduction

Breast cancers are classified by whether or not they express the genes for estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2 (HER2/neu). These three receptors are known to help the cancers develop, and the most successful breast cancer treatments are hormone-based drugs that directly target these receptors. Breast cancers that have spread to distant sites remain largely incurable; they are managed by various combinations of therapies. The goals of treatment are focused on prolonging overall survival without having a negative impact on quality of life. Optimizing treatment involves an individualized approach based on a number of factors, including previous regimens and responses to them, the specific tumor biology, growth rate of the disease, risks for toxicity, and patient preference and comorbidities. The relative benefits and toxicities of various regimens are important considerations.

The use of combination therapy versus monotherapy or sequential single agents remains a strongly debated issue. As evidence of the controversial nature of the treatment approaches, the FDA recently announced its decision recommending withdrawing Avastin (bevacizumab) as a treatment for breast cancer, although the decision is being appealed. Since there is currently no single standard of care for the management of metastatic breast cancers and since practice patterns vary widely, the purpose of this report is to provide updated data on how U.S. oncologists currently manage metastatic breast cancers.